Join to View Full Profile
460 W 10th AveColumbus, OH 43210
Phone+1 614-293-6529
Fax+1 614-293-9429
Dr. Wesolowski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2007 - 2010- Cleveland Clinic FoundationResidency, Internal Medicine, 2004 - 2007
State University of New York Downstate Medical Center College of MedicineClass of 2004
Certifications & Licensure
OH State Medical License 2004 - 2025
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I Start of enrollment: 2011 Oct 01
- Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors Start of enrollment: 2012 May 01
- AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
- Join now to see all
Publications & Presentations
PubMed
- HSR25-154: Treatment Patterns and Prognosis of Patients With HER2-Negative Early Breast Cancer and Germline Pathogenic Variants in BRCA1, BRCA2, ATM, CHEK2 and PALB2.Vishnu Prasath, Andrea Riner, Joanne Kim, Akia Clark, Brandon Slover
Journal of the National Comprehensive Cancer Network. 2025-03-28 - The role of oxytocin in mediating the relationships between social factors and chemotherapy-associated cognitive decline in female patients with breast cancer.Melina M Seng, Seth Adarkwah Yiadom, Lauren D Otto-Dobos, Sagar D Sardesai, Nicole O Williams
Psychoneuroendocrinology. 2025-03-15 - CNPY2 in Solid Tumors: Mechanisms, Biomarker Potential, and Therapeutic Implications.Sayan Mullick Chowdhury, Feng Hong, Christian Rolfo, Zihai Li, Kai He
Biology. 2025-02-18
Journal Articles
- Modeling Combination Therapy for Breast Cancer with BET and Immune Checkpoint InhibitorsRobert Wesolowski, Andrew Stiff, Proceedings of the National Academy of Sciences
Press Mentions
Bexion Pharmaceuticals, Inc. Announces Publication of Phase 1 Data for BXQ-350 in Advanced Solid TumorsOctober 31st, 2024- Ohio State's Novel DHODH Inhibitor Enters First Human TrialsSeptember 16th, 2024
- Sanofi’s, AstraZeneca’s and Radius’ Oral SERDs Could Establish Clinical Worth in ER+ Breast Cancer by Showing Similar Efficacy to Faslodex, Experts SayApril 6th, 2021
- Join now to see all
Grant Support
- Training Hematology and Oncology Fellows in Clinical ResearchOHIO STATE UNIVERSITY2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
